公开(公告)号：US11970535B2

公开(公告)日：2024-04-30

申请号：US17114835

申请日：2020-12-08

Applicant: INNATE PHARMA

Inventor： Carine Paturel ,  Helene Sicard

IPC: A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61P35/00 ,  C07K16/3061 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: This invention relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.

公开(公告)号：US11377503B2

公开(公告)日：2022-07-05

申请号：US16443744

申请日：2019-06-17

Applicant: Innate Pharma

Inventor： Stéphanie Chanteux ,  Laurent Gauthier ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

公开(公告)号：US10766966B2

公开(公告)日：2020-09-08

申请号：US15517991

申请日：2015-10-09

Applicant: INNATE PHARMA

Inventor： Ivan Perrot ,  Carine Paturel ,  Laurent Gauthier

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/40 ,  C07K16/30

Abstract: This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5′ nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.

公开(公告)号：US20160347853A1

公开(公告)日：2016-12-01

申请号：US15204851

申请日：2016-07-07

Applicant: Innate Pharma

Inventor： Laurent Gauthier ,  Catherine Massacrier ,  Yannis Morel ,  Carine Paturel

IPC: C07K16/28 ,  A61K45/06 ,  A61K47/48 ,  A61K39/395

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6849 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/54 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like.

Abstract translation: 本发明涉及特异性结合TLR3的抗体（例如单克隆抗体），抗体片段及其衍生物，并且任选进一步调节，例如， 抑制信号。 本发明还涉及产生这种抗体的细胞; 制备此类抗体的方法; 抗体的片段，变体和衍生物; 包含它们的药物组合物; 使用抗体诊断，治疗或预防疾病的方法，例如， 自身免疫性疾病，炎症性疾病等。

公开(公告)号：US11572410B2

公开(公告)日：2023-02-07

申请号：US16924288

申请日：2020-07-09

Applicant: INNATE PHARMA

Inventor： Pascale Andre ,  Mathieu Blery ,  Carine Paturel ,  Nicolai Wagtmann

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.

公开(公告)号：US20200024357A1

公开(公告)日：2020-01-23

申请号：US16443744

申请日：2019-06-17

Applicant: Innate Pharma

Inventor： Stéphanie Chanteux ,  Laurent Gauthier ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

公开(公告)号：US09944712B2

公开(公告)日：2018-04-17

申请号：US14403171

申请日：2013-05-30

Applicant: INNATE PHARMA

Inventor： Cécile Bonnafous ,  Laurent Gauthier ,  Yannis Morel ,  Carine Paturel ,  Ivan Perrot

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/68 ,  C07K14/705 ,  A61K39/00

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.

公开(公告)号：US12037392B2

公开(公告)日：2024-07-16

申请号：US17225160

申请日：2021-04-08

Applicant: INNATE PHARMA

Inventor： Pascale Andre ,  Mathieu Blery ,  Carine Paturel ,  Caroline Soulas ,  Nicolaï Wagtmann

IPC: C07K16/30 ,  A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K39/39558 ,  C07K16/2863 ,  C07K16/30 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/76 ,  C07K2317/92 ,  A61K39/39558 ,  A61K2300/00

Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.

公开(公告)号：US20230340143A1

公开(公告)日：2023-10-26

申请号：US18168522

申请日：2023-02-13

Applicant: Innate Pharma ,  OREGA BIOTECH

Inventor： Stéphanie Chanteux ,  Nicolas Gourdin ,  Carine Paturel ,  Ivan Perrot ,  Benjamin Rossi

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  G01N33/574 ,  A61P35/00

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  G01N33/57492 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

公开(公告)号：US11130817B2

公开(公告)日：2021-09-28

申请号：US15767661

申请日：2016-10-11

Applicant: INNATE PHARMA ,  CENTRE LEON BERARD

Inventor： Christophe Caux ,  Laurent Gauthier ,  Nicolas Gourdin ,  Christine Menetrier-Caux ,  Carine Paturel ,  Ivan Perrot

IPC: C07K16/28 ,  C07K16/40 ,  A61P35/00

Abstract: Provided are antibodies that bind and inhibit CD73, are capable of increasing the proliferation of T cells in the presence of CD39-expressing B cells and ATP. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent cancer.